IGI Logo

Biocon is currently trading at Rs. 382.80, up by 24.20 points or 6.75% from its previous closing of Rs. 358.60 on the BSE.

The scrip opened at Rs. 360.45 and has touched a high and low of Rs. 389.00 and Rs. 360.45 respectively. So far 1190136 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 5 has touched a 52 week high of Rs. 395.65 on 17-Sep-2024 and a 52 week low of Rs. 244.40 on 20-Mar-2024.

Last one week high and low of the scrip stood at Rs. 389.00 and Rs. 356.50 respectively. The current market cap of the company is Rs. 45946.96 crore.

The promoters holding in the company stood at 60.64%, while Institutions and Non-Institutions held 20.37% and 18.99% respectively.

Biocon’s subsidiary -- Biocon Biologics (BBL) has received an approval from the Pharmaceuticals and Medical Devices Agency (PMDA) of Japan for Ustekinumab BS subcutaneous injection [YD], a biosimilar to the reference product, Stelara (Ustekinumab). The biosimilar Ustekinumab has been developed and manufactured by the Company and will be commercialized and marketed in Japan by the Company’s exclusive commercial partner, Yoshindo Inc.

Ustekinumab, a monoclonal antibody, is approved for the treatment of Psoriasis Vulgaris and Psoriatic Arthritis (PsA). Biocon Biologics previously notified the Stock Exchange on August 29, 2024, that the Company had entered into a settlement and licensing agreement with Janssen Biotech Inc., Janssen Sciences Ireland, and Johnson & Johnson (collectively known as Janssen) to commercialize Ustekinumab in Japan, upon regulatory approval.

Biocon is India’s largest and Asia’s leading Biotechnology Company with a strategic focus on biopharmaceuticals and research services. It is a fully integrated, innovation driven biopharma enterprise offering affordable solutions for chronic diseases to patient's worldwide.